Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
87.00
+1.29 (1.51%)
Jun 11, 2026, 12:42 PM EDT - Market open

Rhythm Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $138.2. The average 1-year stock price forecast is 58.85% higher than the current stock price, while the lowest is $105 (+20.69%) and the highest is $159 (+82.76%).

Price Target: $138.2 (+58.85%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$105$138.2$142$159
Change+20.69%+58.85%+63.22%+82.76%
* Price targets were last updated on May 11, 2026.

Analyst Ratings

The average analyst rating for Rhythm Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy111111111111
Buy344444
Hold111111
Sell000000
Strong Sell000000
Total151616161616

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 20, 2026
Guggenheim
Guggenheim
Buy
Reiterates
$143
BuyReiterates$143+64.37%May 11, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$105
BuyReiterates$105+20.69%May 11, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$131$133
BuyMaintains$131$133+52.87%May 8, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$140$143
BuyMaintains$140$143+64.37%May 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
298.09M
from 189.76M
Increased by 57.09%
Revenue Next Year
540.99M
from 298.09M
Increased by 81.49%
EPS This Year
-3.29
from -3.11
EPS Next Year
-0.79
from -3.29
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.15M23.64M77.43M130.13M189.76M298.09M
Revenue Growth
-649.46%227.56%68.06%45.83%57.09%
Gross Profit
2.56M21.51M68.13M116.76M170.27M268.77M
Gross Margin
81.01%90.98%87.99%89.73%89.73%90.17%
Operating Income
-170.06M-179.16M-184.36M-173.10M-192.02M-207.32M
Net Income
-69.61M-181.12M-184.68M-260.60M-196.54M-216.77M
EPS
-----3.11-3.29
Free Cash Flow
-57.05M-105.11M-91.47M-81.99M-145.98M-218.33M
No. Analysts
-----16
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High321.0M
Avg298.1M
Low273.6M

Revenue Growth

Revenue Growth202620272028
High
69.2%
Avg
57.1%
Low
44.2%

EPS Forecast

EPS202620272028
High-
Avg-3.29
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-